Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCCC: Antiviral Prophylaxis for CMV in Critical Care
NCT01503918Phase 2Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Jan 2012
- Primary completion
- Jan 2014
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of valaciclovir, valganciclovir in cytomegalovirus infection (CMV), sponsored by University Hospitals Birmingham. Started Jan 2012; status: completed.
02
Drugs
valaciclovirvalganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01503918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01503918.